MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Recursion Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

5.83 5.62

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

5.52

Massimo

6.21

Metriche Chiave

By Trading Economics

Entrata

-24M

-202M

Vendite

10M

15M

Margine di Profitto

-1,373.259

Dipendenti

800

EBITDA

-26M

-191M

Raccomandazioni

By TipRanks

Raccomandazioni

Neutrale

Previsioni per 12 mesi

+15.96% upside

Dividendi

By Dow Jones

Utili prossimi

7 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-27M

2.3B

Apertura precedente

0.21

Chiusura precedente

5.83

Notizie sul Sentiment di mercato

By Acuity

67%

33%

328 / 376 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Recursion Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

18 lug 2025, 21:01 UTC

Utili

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

18 lug 2025, 20:50 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

18 lug 2025, 20:50 UTC

Discorsi di Mercato
Utili

Auto & Transport Roundup: Market Talk

18 lug 2025, 20:50 UTC

Discorsi di Mercato
Utili

Basic Materials Roundup: Market Talk

18 lug 2025, 20:46 UTC

Utili

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

18 lug 2025, 20:39 UTC

Acquisizioni, Fusioni, Takeovers

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 lug 2025, 20:36 UTC

Utili

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

18 lug 2025, 20:16 UTC

Acquisizioni, Fusioni, Takeovers

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

18 lug 2025, 20:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

18 lug 2025, 20:02 UTC

Discorsi di Mercato

Gold Higher to Close Out Week -- Market Talk

18 lug 2025, 19:14 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

18 lug 2025, 19:06 UTC

Discorsi di Mercato

Oil Futures Snap Two-Week Winning Streak -- Market Talk

18 lug 2025, 18:24 UTC

Utili

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

18 lug 2025, 18:19 UTC

Utili

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

18 lug 2025, 18:11 UTC

Acquisizioni, Fusioni, Takeovers

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

18 lug 2025, 18:11 UTC

Utili

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

18 lug 2025, 17:35 UTC

Discorsi di Mercato

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

18 lug 2025, 16:29 UTC

Discorsi di Mercato

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

18 lug 2025, 16:28 UTC

Acquisizioni, Fusioni, Takeovers

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 lug 2025, 16:22 UTC

Utili

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

18 lug 2025, 16:20 UTC

Discorsi di Mercato
Utili

Financial Services Roundup: Market Talk

18 lug 2025, 16:20 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

18 lug 2025, 16:20 UTC

Discorsi di Mercato
Utili

Auto & Transport Roundup: Market Talk

18 lug 2025, 16:20 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Energy & Utilities Roundup: Market Talk

18 lug 2025, 16:20 UTC

Discorsi di Mercato
Utili

Basic Materials Roundup: Market Talk

18 lug 2025, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

18 lug 2025, 16:04 UTC

Utili

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

18 lug 2025, 15:58 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

18 lug 2025, 15:58 UTC

Discorsi di Mercato

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

18 lug 2025, 15:47 UTC

Discorsi di Mercato
Utili

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Confronto tra pari

Modifica del prezzo

Recursion Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

15.96% in crescita

Previsioni per 12 mesi

Media 6.25 USD  15.96%

Alto 8 USD

Basso 4 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Recursion Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

5 ratings

1

Acquista

4

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

4.15 / 4.75Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

328 / 376 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.